The Next Drug Crisis Has Already Started: Rethinking Surveillance, Toxicology and Public Health in the Era of Rapidly Evolving Psychoactive Substances

Vollständiger Abstract

Worum geht es in dieser Arbeit?

The global drug landscape is undergoing its most profound transformation since the emergence of the modern illicit drug market during the twentieth century. For decades, drug policies, analytical toxicology, forensic science, and public health responses have been developed around a relatively limited number of well-characterized substances, including heroin, cocaine, cannabis, and amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA). Although new psychoactive substances (NPS) have received increasing attention over the last two decades, they are often considered an additional drug category rather than evidence of a much broader transformation affecting the entire drug ecosystem. This work argues that the contemporary challenge is no longer the emergence of isolated novel compounds but the transition from relatively stable drug markets to dynamic, synthetic, and continuously evolving psychoactive ecosystems. Drug production is increasingly detached from agricultural constraints, driven instead by advances in synthetic chemistry, global precursor markets, digital technologies, and highly adaptive criminal networks capable of rapidly modifying molecular structures to evade legislation and analytical detection. Simultaneously, counterfeit pharmaceuticals, semi-synthetic cannabinoids, highly potent synthetic opioids, novel stimulants, and complex patterns of polysubstance use are blurring traditional boundaries between illicit drugs, medicines, and consumer products. Future preparedness will depend less on identifying individual new substances than on developing integrated scientific predictive systems capable of anticipating rapidly evolving drug threats before they become widespread public health crises.